This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
| less than a minute read

Licensing deals and the UPC - what you need to know

If you have been following the UPC "saga", you already know that it's currently at the final stage - which means that we should witness the beginning of the new patent system at the end of 2022 / early 2023.

With the new UPC system having certain advantages and disadvantages, anyone planning licensing or collaboration deals should agree a strategy related to European patents in their agreements – an exercise better started sooner rather than later.

So how do you make your licences and patent strategy UPC-ready? We have prepared a detailed note on what needs to be done, which you can read on the Bristows UPC hub, here, and a summary of some of the risks facing life sciences companies in our On The Pulse publication, here.

With the new UPC system having certain advantages and disadvantages, anyone planning licensing or collaboration deals should agree a strategy related to European patents in their agreements – an exercise better started sooner rather than later.

Tags

commercial and ip transactions, life sciences, upc, biotech

Tweets on this subject